Taysha Gene Therapies (TSHA): Revisiting Valuation After TSHA-102 Breakthrough Designation and Trial Milestones

Simply Wall St.2025-12-24

Taysha Gene Therapies (TSHA) has caught investors attention after securing FDA Breakthrough Therapy Designation for its Rett syndrome candidate TSHA-102 and locking in a pivotal REVEAL trial design ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593426277?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-24 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593426277","market":"nz","top_or_hot":-1,"title":"Taysha Gene Therapies (TSHA): Revisiting Valuation After TSHA-102 Breakthrough Designation and Trial Milestones","media":"Simply Wall St.","content":"<div>\n<p>Taysha Gene Therapies (TSHA) has caught investors attention after securing FDA Breakthrough Therapy Designation for its Rett syndrome candidate TSHA-102 and locking in a pivotal REVEAL trial design ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-revisiting-valuation-after-tsha-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taysha Gene Therapies (TSHA): Revisiting Valuation After TSHA-102 Breakthrough Designation and Trial Milestones</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaysha Gene Therapies (TSHA): Revisiting Valuation After TSHA-102 Breakthrough Designation and Trial Milestones\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-24 10:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-revisiting-valuation-after-tsha-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Taysha Gene Therapies (TSHA) has caught investors attention after securing FDA Breakthrough Therapy Designation for its Rett syndrome candidate TSHA-102 and locking in a pivotal REVEAL trial design ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-revisiting-valuation-after-tsha-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-revisiting-valuation-after-tsha-1","article_id":"2593426277","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-revisiting-valuation-after-tsha-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593426277","pubTimestamp":1766543738,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Taysha Gene Therapies (TSHA) has caught investors attention after securing FDA Breakthrough Therapy Designation for its Rett syndrome candidate TSHA-102 and locking in a pivotal REVEAL trial design with an interim analysis aimed at a future filing.\nSee our latest analysis for Taysha Gene Therapies.\nThe excitement around TSHA-102 and the FDA Breakthrough Therapy Designation has helped fuel a powerful rerating, with the stock posting a 30 day share price return of about 29 percent and a roughly...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TSHA":"Taysha Gene Therapies, Inc."},"translate_title":"Taysha Gene Therapies(TSHA)：在TSHA-102突破性指定和试验里程碑后重新审视估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSHA":1.5},"content_text":"Taysha Gene Therapies (TSHA) has caught investors attention after securing FDA Breakthrough Therapy Designation for its Rett syndrome candidate TSHA-102 and locking in a pivotal REVEAL trial design with an interim analysis aimed at a future filing. See our latest analysis for Taysha Gene Therapies. The excitement around TSHA-102 and the FDA Breakthrough Therapy Designation has helped fuel a powerful rerating, with the stock posting a 30 day share price return of about 29 percent and a roughly 209 percent year to date share price return, even though the five year total shareholder return remains deeply negative. This shows how quickly sentiment has flipped as investors reassess both upside potential and risk. If this kind of high risk biotech turnaround has your attention, it could be a good moment to scan other healthcare stocks that might be quietly setting up similar inflection points. Given the stock has more than tripled this year but still trades at a steep discount to analyst targets, is Taysha Gene Therapies an underappreciated growth story, or is the market already pricing in years of future progress? Most Popular Narrative Narrative: 46% Undervalued Taysha Gene Therapies last closed at $5.71, while the most popular narrative pegs fair value closer to $10.57, framing a sizable upside gap.  The analysts have a consensus price target of $6.55 for Taysha Gene Therapies based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $8.0, and the most bearish reporting a price target of just $5.0.  Read the complete narrative. Curious how projected triple digit revenue growth, a step change in margins, and a sky high future earnings multiple all combine to justify that valuation gap? The full narrative unpacks the bold assumptions behind this aggressive long term earnings trajectory and the premium price tag it implies. Result: Fair Value of $10.57 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, meaningful delays in regulatory approvals or underwhelming long term TSHA-102 data could quickly challenge today’s optimistic valuation narrative. Find out about the key risks to this Taysha Gene Therapies narrative.  Build Your Own Taysha Gene Therapies Narrative If you are not fully aligned with this view or prefer hands on analysis, you can build a personalised narrative in under three minutes: Do it your way. A great starting point for your Taysha Gene Therapies research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision. Ready for more high conviction ideas? Before you move on, put Simply Wall Street to work for you by uncovering fresh, data driven opportunities that could quietly reshape your portfolio’s long term returns.  Capitalize on mispriced opportunities by targeting these 908 undervalued stocks based on cash flows that may offer significant upside if the market catches up to their fundamentals. Turbocharge your growth potential by zeroing in on these 24 AI penny stocks shaping the next wave of innovation across multiple industries. Lock in stronger income streams by focusing on these 10 dividend stocks with yields > 3% that can help support both yield and long term stability.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechValuation is complex, but we're here to simplify it.Discover if Taysha Gene Therapies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593426277","isCrawlerRequest":true}